ACU-4429: Interim Phase IIa data

Interim data from the double-blind, U.S. Phase IIa ENVISION Clarity trial in 56 patients showed that once-daily oral ACU-4429 led to dose-dependent inhibition of the visual cycle from baseline to day ...